Loading
Viking Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Aubuchon Neil William, was filed 10 Mar 2026.
Viking Therapeutics, Inc.: what insiders have been doing
This page follows insider dealings at Viking Therapeutics, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector based in San Diego, United States. The group dates from 2012. 13 insiders have disclosed 46 filings since 22 October 2025.
Purchases and sales both appear in the filings: 1 purchase (1 insider, €129k) and 20 sales (5 insiders, €19.2M). Taken together, the sales exceed the purchases by €19.0M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. One trade stands out by size: a sale of €4.3M from Lian Brian, disclosed on 29 July 2026, or 0.10% of market capitalisation. Among those who bought: 1 senior executive.
The last purchase on record was published on 10 March 2026, which is 228 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Across the 3,171 companies tracked on its exchange, the median is 24 filings; at 46 filings, this issuer sits above that mark. Since 2016, the database holds 10 purchases and 112 sales by insiders of the company. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists net income at -359.6 m USD.
Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
330
Thresholds
n/a
Buy Volume
€859,665
10 ops. · all time
Sell Volume
€139M
112 ops. · all time
Who traded when
BuySaleBrian Lian9 sales
Greg Zante9 sales
Marianna Mancini9 sales
Macartney Lawson1 sale
Matthew W. Foehr1 sale
Neil William Aubuchon1 buy
+2 other insiders
Since the insiders bought
- -18.3%Entry US$35.76 · Close at T+90 US$29.23
- +40.1%Entry US$24.22 · Close at T+365 US$33.93
- +749.8%Entry US$2.55 · Close at T+365 US$21.67
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Viking Therapeutics, Inc. Strong Buy (bullish), based on 20 analysts. Average price target: US$94.10.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$26.38
Analyst consensus
20 analystsStrong buy
US$38.00Target US$94.10(+257%)US$125.00
Income statement
EBITDA-US$392.9M
Net income-US$359.6M0.0% margin
Valuation
PER (forward)-6.1x
P/Book7.5x
Beta0.65
Balance sheet & cash
Market capUS$3.4B
Total debtUS$137k
Free Cash Flow-US$278.7M
Debt / Equity1%
Profitability & ownership
ROE-88.9%
ROA-51.9%
% insiders2.8%
% institutions60.5%
Last declaration on 7 August 2026
Declarations330 total
6,333 shares0Common Stock, par value $0.00001 per shareSEC:0002144542-26-000004:0
21,217 shares@ US$33.47040.015% mcap100.0% of flowCommonSEC144:0001950047-26-007380
148,517 shares@ US$33.31530.10% mcap100.0% of flowCommonSEC144:0001950047-26-007394
18,217 shares@ US$33.46520.013% mcap100.0% of flowCommonSEC144:0001950047-26-007376
221,667 shares0Common Stock, par value $0.00001 per shareSEC:0001193125-26-324448:0
31,667 shares0Common Stock, par value $0.00001 per shareSEC:0001193125-26-324446:0
31,667 shares0Common Stock, par value $0.00001 per shareSEC:0001193125-26-324447:0
148,517 shares@ US$33.31530.10% mcap43.6% of flowCommon Stock, par value $0.00001 per shareSEC:0001193125-26-324448:1
18,217 shares@ US$33.46520.013% mcap53.4% of flowCommon Stock, par value $0.00001 per shareSEC:0001193125-26-324446:1
21,217 shares@ US$33.47040.015% mcap56.2% of flowCommon Stock, par value $0.00001 per shareSEC:0001193125-26-324447:1
4,475 shares@ US$33.50100.0% of flowCommon Stock, par value $0.00001 per shareSEC:0001193125-26-100581:0
Canonical exit: 8 Jun 2026 (T+90)
3,150 shares0Common Stock, par value $0.00001 per shareSEC:0001193125-26-003109:2
224,080 shares0Common Stock, par value $0.00001 per shareSEC:0001193125-26-003113:1
32,049 shares0Common Stock, par value $0.00001 per shareSEC:0001193125-26-003115:1
32,049 shares0Common Stock, par value $0.00001 per shareSEC:0001193125-26-003116:1
1,500 shares@ US$32.090.1% of flowCommon Stock, par value $0.00001 per shareSEC:0001193125-26-003116:5
16,000 shares@ US$35.1147.0% of flowCommon Stock, par value $0.00001 per shareSEC:0001193125-26-003109:1
132,454 shares@ US$32.293.4% of flowCommon Stock, par value $0.00001 per shareSEC:0001193125-26-003113:2
53,279 shares@ US$33.381.4% of flowCommon Stock, par value $0.00001 per shareSEC:0001193125-26-003113:3
41,276 shares@ US$34.221.1% of flowCommon Stock, par value $0.00001 per shareSEC:0001193125-26-003113:4
6,400 shares@ US$35.070.2% of flowCommon Stock, par value $0.00001 per shareSEC:0001193125-26-003113:5
31,961 shares@ US$32.292.3% of flowCommon Stock, par value $0.00001 per shareSEC:0001193125-26-003115:2
13,600 shares@ US$33.371.0% of flowCommon Stock, par value $0.00001 per shareSEC:0001193125-26-003115:3
10,500 shares@ US$34.220.8% of flowCommon Stock, par value $0.00001 per shareSEC:0001193125-26-003115:4
1,600 shares@ US$35.070.1% of flowCommon Stock, par value $0.00001 per shareSEC:0001193125-26-003115:5
25 of 330 declarations
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company listed on the NASDAQ in the United States. Headquartered in San Diego, California, the company focuses on developing novel therapies for metabolic and endocrine disorders. Founded by Brian Lian, Ph.D., Viking has built its identity around metabolism-focused drug discovery, aiming to address large unmet medical needs in obesity, lipid disorders, and liver disease. The company’s leadership and operating footprint remain centered in the United States, with R&D activities anchored in San Diego. ([vikingtherapeutics.com](https://vikingtherapeutics.com/about/?utm_source=openai))
Viking’s most important program is VK2735, a wholly owned dual GLP-1/GIP agonist being advanced for obesity and other metabolic disorders. This asset is the company’s lead strategic driver. In 2025, Viking initiated its VANQUISH Phase 3 registration program for the subcutaneous formulation of VK2735, while also advancing an oral tablet version. The company later reported positive Phase 2 oral data showing meaningful weight loss over 13 weeks, and in 2026 it presented additional oral-program data at the European Congress on Obesity. These developments underscore Viking’s push to compete in a highly attractive but intensely crowded obesity market through differentiation in both mechanism and dosing convenience. ([ir.vikingtherapeutics.com](https://ir.vikingtherapeutics.com/2025-06-25-Viking-Therapeutics-Announces-Initiation-of-Phase-3-Obesity-Clinical-Program-with-GLP-1-GIP-Agonist-VK2735?utm_source=openai))
Read moreShow less
Beyond obesity, Viking is developing VK2809, an orally available selective thyroid hormone receptor beta agonist designed for lipid disorders and metabolic liver disease, including MASH/NASH. The company reported encouraging Phase 2b histology data in 2024, which helped reinforce confidence in the broader thyroid receptor beta platform. Viking is also advancing VK0214, another oral TRβ agonist being explored for X-linked adrenoleukodystrophy, highlighting a pipeline that extends beyond a single indication while staying within the company’s core metabolic and endocrine expertise. ([vikingtherapeutics.com](https://vikingtherapeutics.com/pipeline/vk0214/?utm_source=openai))
From a competitive standpoint, Viking is still a development-stage biotech rather than a commercial-stage pharmaceutical company. It competes against larger, better-capitalized players in obesity and metabolic disease, so its investment case depends heavily on clinical execution, regulatory progress, and eventual commercialization or partnership potential. Its portfolio is built around potentially differentiated, small-molecule or peptide-based programs that could offer practical advantages versus incumbent therapies, but the company remains exposed to the typical binary risks of clinical development. ([vikingtherapeutics.com](https://vikingtherapeutics.com/?utm_source=openai))
Recent milestones have been particularly important for the equity story: phase 3 initiation for VK2735, positive oral obesity data, and continued presentation of data across major scientific meetings in 2026. For investors, Viking Therapeutics represents a high-upside U.S. NASDAQ-listed biotech with a focused pipeline, substantial clinical catalysts, and a concentrated risk profile tied to obesity and metabolic-disease readouts. ([ir.vikingtherapeutics.com](https://ir.vikingtherapeutics.com/2025-06-25-Viking-Therapeutics-Announces-Initiation-of-Phase-3-Obesity-Clinical-Program-with-GLP-1-GIP-Agonist-VK2735?utm_source=openai))
